262 related articles for article (PubMed ID: 27581836)
81. [MGMT analysis in gliomas].
Quillien V; Vauléon E; Saikali S; Lesimple T; Hamlat A; Etcheverry A; Mosser J
Bull Cancer; 2011 Mar; 98(3):291-303. PubMed ID: 21459716
[TBL] [Abstract][Full Text] [Related]
82. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection.
Touma W; Hoostal S; Peterson RA; Wiernik A; SantaCruz KS; Lou E
J Clin Neurosci; 2017 Jul; 41():75-77. PubMed ID: 28291643
[TBL] [Abstract][Full Text] [Related]
83. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
Kato T; Natsume A; Toda H; Iwamizu H; Sugita T; Hachisu R; Watanabe R; Yuki K; Motomura K; Bankiewicz K; Wakabayashi T
Gene Ther; 2010 Nov; 17(11):1363-71. PubMed ID: 20520650
[TBL] [Abstract][Full Text] [Related]
84. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Hirohata T; Ishii Y; Matsuno A
Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
[TBL] [Abstract][Full Text] [Related]
85. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
86. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
[TBL] [Abstract][Full Text] [Related]
87. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Koumarianou A; Kaltsas G; Kulke MH; Oberg K; Strosberg JR; Spada F; Galdy S; Barberis M; Fumagalli C; Berruti A; Fazio N
Neuroendocrinology; 2015; 101(4):274-88. PubMed ID: 25924937
[TBL] [Abstract][Full Text] [Related]
88. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
Middlemas DS; Stewart CF; Kirstein MN; Poquette C; Friedman HS; Houghton PJ; Brent TP
Clin Cancer Res; 2000 Mar; 6(3):998-1007. PubMed ID: 10741727
[TBL] [Abstract][Full Text] [Related]
89. [Treatment of glioma with temozolomide].
Nishikawa R
Brain Nerve; 2009 Jul; 61(7):849-54. PubMed ID: 19618863
[TBL] [Abstract][Full Text] [Related]
90. Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas.
Minniti G; Paolini S; Rea MLJ; Isidori A; Scaringi C; Russo I; Osti MF; Cavallo L; Esposito V
J Neurooncol; 2020 Aug; 149(1):123-130. PubMed ID: 32632895
[TBL] [Abstract][Full Text] [Related]
91. Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes.
Das L; Rai A; Salunke P; Ahuja CK; Sood A; Radotra BD; Sood R; Korbonits M; Dutta P
J Endocr Soc; 2022 Feb; 6(2):bvab190. PubMed ID: 35059545
[TBL] [Abstract][Full Text] [Related]
92. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Lenders N; McCormack A
Pituitary; 2018 Apr; 21(2):217-229. PubMed ID: 29299820
[TBL] [Abstract][Full Text] [Related]
93. Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
Campderá M; Palacios N; Aller J; Magallón R; Martín P; Saucedo G; Lilienfeld H; Estrada J
Pituitary; 2016 Apr; 19(2):158-66. PubMed ID: 26586560
[TBL] [Abstract][Full Text] [Related]
94. Temozolomide therapy for aggressive pituitary tumours - current understanding and future perspectives.
Burman P; Lamb L; McCormack A
Rev Endocr Metab Disord; 2020 Jun; 21(2):263-276. PubMed ID: 32147777
[TBL] [Abstract][Full Text] [Related]
95. Aggressive prolactinomas: how to manage?
Lasolle H; Ilie MD; Raverot G
Pituitary; 2020 Feb; 23(1):70-77. PubMed ID: 31617128
[TBL] [Abstract][Full Text] [Related]
96. Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay.
Ishida A; Shichi H; Fukuoka H; Inoshita N; Ogawa W; Yamada S
Pituitary; 2022 Apr; 25(2):238-245. PubMed ID: 34773564
[TBL] [Abstract][Full Text] [Related]
97. Treatment of pituitary neoplasms with temozolomide: A review.
Marucci G
Cancer; 2011 Sep; 117(17):4101-2; author reply 4102. PubMed ID: 21387270
[No Abstract] [Full Text] [Related]
98. Is there a role for early chemotherapy in the management of pituitary adenomas?
Lin AL; Sum MW; DeAngelis LM
Neuro Oncol; 2016 Oct; 18(10):1350-6. PubMed ID: 27106409
[TBL] [Abstract][Full Text] [Related]
99. 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update.
Syro LV; Rotondo F; Ortiz LD; Kovacs K
Endocr Relat Cancer; 2018 Aug; 25(8):T159-T169. PubMed ID: 29535142
[TBL] [Abstract][Full Text] [Related]
100. Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Lamas C; Cámara R; Fajardo C; Remon-Ruiz P; Biagetti B; Guerrero-Pérez F; Araujo-Castro M; Mora M; Hanzu F; Iglesias P; García-Centeno R; Soto A
Front Endocrinol (Lausanne); 2023; 14():1204206. PubMed ID: 37720528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
